Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ethinamate is a short-acting sedative-hypnotic medication of the carbamate class used for the short-term treatment of insomnia. It acts as a central nervous system depressant and shares many effects with barbiturates, though its structure is distinct and its depressant effects are generally milder. Ethinamate has a rapid onset of action when taken orally and a short elimination half-life (about 2.5 hours), making it suitable for sleep induction but not for long-term use due to rapid development of tolerance—typically losing effectiveness after about one week. The precise mechanism of action is unknown; while ethinamate has been shown to inhibit carbonic anhydrases I and II in vitro, this effect does not appear strong enough to explain its clinical activity as a hypnotic[1][2][3][4][8]. Developed in the early 1950s, it was marketed under several brand names but has largely been replaced by safer or more effective alternatives.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ethinamate.